Similar articles

• A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.

  Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y. Tsuruo T, et al. Cancer Res. 1989 Oct 15;49(20):5537-42. Cancer Res. 1989. PMID: 2790778
• Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo.

  Efferth T, Klett T, Mattern J, Osswald H, Pommerenke EW, Stöhr M, Volm M. Efferth T, et al. Anticancer Res. 1991 May-Jun;11(3):1275-9. Anticancer Res. 1991. PMID: 1888160
• Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate.

  Vecchi A, Cairo M, Mantovani A, Sironi M, Spreafico F. Vecchi A, et al. Cancer Treat Rep. 1978 Jan;62(1):111-7. Cancer Treat Rep. 1978. PMID: 626989
• Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.

  Young CW, Raymond V. Young CW, et al. Cancer Treat Rep. 1986 Jan;70(1):51-63. Cancer Treat Rep. 1986. PMID: 2935251 Review. No abstract available.
• Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach.

  Priebe W, Perez-Soler R. Priebe W, et al. Pharmacol Ther. 1993 Nov;60(2):215-34. doi: 10.1016/0163-7258(93)90007-z. Pharmacol Ther. 1993. PMID: 8022858 Review.